Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PATIENT DOSING ONGOING IN CALIPSO-1 TRIAL; ON TRACK TO REPORT CLINICAL DATA FOR CNTY-101 IN PATIENTS WITH B-CELL-MEDIATED AUTOIMMUNE DISEASES BY YEAR-END 2025 CNTY-308, A CAR-IT CELL THERAPY FUNCTIONALLY COMPARABLE TO PRIMARY T CELLS, NOW IN IND-ENABLING STUDIES AS A POTENTIAL TREATMENT FOR B-CELL-MEDIATED DISEASES; PROGRAM EXPECTED TO PROGRESS INTO THE CLINIC IN 2026 DR. BRENT PFEIFFENBERGER, CEO, APPOINTED TO BOARD CHAIR CASH RUNWAY EXTENDED INTO FOURTH QUARTER 2027 PHILADELPHIA, AUG. 14, 2025 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS, INC. (CENTURY', NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN AUTOIMMUNE DISEASE AND CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE. IN THE FIRST HALF OF 2025, WE MADE IMPORTANT BUSINESS DECISIONS TO ENSURE OUR CAPITAL RESOURCE ALLOCATION AND PIPELINE DEVELOPMENT ACTIVITIES ARE CENTERED ON POTENTIALLY TRANSFORMATIONAL CELL THERAPY CANDIDATES AND TECHNOLOGIES.

CENTURY THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

PHILADELPHIA, MAY 28, 2025 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS, INC. (CENTURY', NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN AUTOIMMUNE DISEASE AND CANCER, TODAY ANNOUNCED TWO PRESENTATIONS AT THE UPCOMING EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) 2025 CONGRESS, WHICH IS BEING HELD FROM JUNE 11-14, 2025, AT FIRA DE BARCELONA IN BARCELONA, SPAIN. THE PRESENTATIONS WILL HIGHLIGHT DATA SUPPORTING THE COMPANY'S EMERGING PRECLINICAL CELL THERAPY PIPELINE AND INVESTIGATIONAL PROGRAMS FOR AUTOIMMUNE DISEASES AND CANCER.

CENTURY THERAPEUTICS ANNOUNCES TWO UPCOMING PRESENTATIONS AT THE EULAR 2025 CONGRESS

PHILADELPHIA, MAY 15, 2025 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS, INC. (CENTURY', NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN AUTOIMMUNE DISEASE AND CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

CENTURY THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

PHILADELPHIA, APRIL 28, 2025 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS, INC. (CENTURY', NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN AUTOIMMUNE DISEASE AND CANCER, TODAY ANNOUNCED TWO PRESENTATIONS AT THE UPCOMING AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 28TH ANNUAL MEETING, WHICH IS BEING HELD FROM MAY 13-17, 2025, AT THE NEW ORLEANS ERNEST N. MORIAL CONVENTION CENTER IN NEW ORLEANS, LA. THE PRESENTATIONS WILL HIGHLIGHT DATA SUPPORTING THE COMPANY'S EMERGING PRECLINICAL CELL THERAPY PIPELINE AND INVESTIGATIONAL PROGRAMS FOR AUTOIMMUNE DISEASES AND CANCER.

CENTURY THERAPEUTICS ANNOUNCES TWO UPCOMING PRESENTATIONS AT THE ASGCT 28TH ANNUAL MEETING

PHILADELPHIA, MARCH 19, 2025 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS, INC. (CENTURY', NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN AUTOIMMUNE DISEASE AND CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FULL YEAR 2024.

CENTURY THERAPEUTICS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

PHILADELPHIA, NOV. 26, 2024 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS (NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN IMMUNO-ONCOLOGY AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING EVENTS AT THE PIPER SANDLER 36TH ANNUAL HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 4, 2024:

CENTURY THERAPEUTICS TO PRESENT AT THE PIPER SANDLER 36TH ANNUAL HEALTHCARE CONFERENCE

 EXPANSION OF PHASE 1 CALIPSO-1 TRIAL OF CNTY-101 IN AUTOIMMUNE DISEASE TO INCLUDE DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHY 

CENTURY THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

PHILADELPHIA, NOV. 04, 2024 (GLOBE NEWSWIRE) -- CENTURY THERAPEUTICS (NASDAQ: IPSC), AN INNOVATIVE BIOTECHNOLOGY COMPANY DEVELOPING INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELL THERAPIES IN IMMUNO-ONCOLOGY AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT BRENT PFEIFFENBERGER, PHARM.D., CHIEF EXECUTIVE OFFICER, AND CHAD COWAN, PH.D., CHIEF SCIENTIFIC OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT GUGGENHEIM'S INAUGURAL HEALTHCARE INNOVATION CONFERENCE ON TUESDAY, NOVEMBER 12, 2024 AT 9:30AM ET.

CENTURY THERAPEUTICS TO PRESENT AT GUGGENHEIM'S INAUGURAL HEALTHCARE INNOVATION CONFERENCE

- MORGAN CONN, PH.D., SEASONED BIOTECH EXECUTIVE WITH EXPERTISE IN FINANCING, BUSINESS DEVELOPMENT, AND CORPORATE STRATEGY, APPOINTED AS CHIEF FINANCIAL OFFICER -

CENTURY THERAPEUTICS STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENTS OF CHIEF FINANCIAL OFFICER AND CHIEF SCIENTIFIC OFFICER

 INITIATION OF PHASE 1 CALIPSO-1 TRIAL OF CNTY-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS, MARKING STRATEGIC EXPANSION INTO AUTOIMMUNE DISEASE; PROTOCOL AMENDED TO INCLUDE ADDITIONAL COHORT OF LUPUS NEPHRITIS PATIENTS 

CENTURY THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

IN ONGOING DOSE ESCALATION, CNTY-101 HAS DEMONSTRATED A MANAGEABLE SAFETY PROFILE WITH NO OBSERVED DLTS OR GVHD AND WITH MAJORITY OF PATIENTS TREATED IN OUTPATIENT SETTING

Century Therapeutics, Inc.

IPSC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Century Therapeutics, Inc.

IPSC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IPSC